
The new value calculus
As employers confront rising healthcare costs, volatile stop-loss renewals and growing scrutiny of benefits expenditure, captives are evolving from a cost-saving mechanism into a more strategic tool for employee benefits financing. Captive Review investigates.
For employers, the financial case for funding employee benefits through a captive has traditionally centred on reducing insurance costs and retaining underwriting profits that would otherwise accrue to commercial insurers.
Today, that calculation is becoming more sophisticated. Persistent medical inflation, escalating specialty pharmacy costs and a hardening stop-loss market are prompting organisations to reconsider not just how much they pay to transfer risk, but how much control and long-term value they surrender in doing so.
“The financial case has evolved from simply reducing insurance costs to creating a more strategic and controllable funding approach,” says Prabal Lakhanpal, senior vice president at Spring Group.
While the potential to capture underwriting gains and reduce frictional costs remains important, the appeal increasingly lies in the ability to manage volatility, improve budget predictability and align benefits financing with wider corporate risk management objectives.
Sebastian Willmanowski, financing leader international, Marsh Health and Benefits, Multinational, highlights the economic distinction between captives and alternative arrangements. Although multinational pooling can enable employers to participate in profits, he says, “using a captive remains the only vehicle for clients to retain all insurer margins”.
Employee benefits might offer lower margins than some other insurance lines, but their risk characteristics are attractive. Willmanowski points to “better predictability with a high frequency low(er) severity exposure”, making benefits a potentially valuable addition to a captive's portfolio.
Taking control of the pricing equation
One of the strongest arguments for captive funding is the opportunity to reduce dependence on commercial insurance pricing cycles.
Under traditional arrangements, an employer's renewal terms can be influenced by the insurer's overall portfolio performance, reinsurance costs and appetite for risk. Even organisations with favourable claims experience might face substantial premium increases if their insurer is experiencing losses elsewhere in its book.
For employers already managing pressure on healthcare budgets, this disconnect between individual performance and market pricing makes forecasting increasingly difficult.
Captives offer an alternative by allowing organisations to retain a defined layer of risk, participate directly in their own underwriting results and take a longer-term view of claims experience. Although they cannot eliminate underlying medical or pharmacy inflation, they can provide greater transparency into its drivers and create more opportunities to manage costs.
“Over time, favourable years generate surplus that can help offset less favourable years, creating a smoothing effect that improves predictability and budgeting,” Lakhanpal explains.
Willmanowski emphasises the additional flexibility this creates around pricing and plan design. Captives can establish their own underwriting and pricing methodologies, assess experience over longer periods than a conventional annual renewal cycle and, in some cases, provide multi-year guarantees to local subsidiaries.
This can be particularly valuable when a spike in claims would otherwise trigger a significant commercial premium increase. A captive can take a different view of the underlying risk, rather than automatically pass the immediate impact through to the employer.
For multinational businesses, this flexibility can also help deliver more consistent benefits financing across different markets while allowing individual arrangements to reflect local requirements.
As Willmanowski puts it, the objective is to provide “long-term pricing stability for the local subsidiaries”.
A lower insurance premium might improve the immediate financial position, but greater predictability in the underlying healthcare spend can be more valuable to an organisation seeking to manage budgets over several years.
Beyond underwriting gains
Retaining underwriting profit remains a central component of the business case, but focusing exclusively on immediate savings risks overlooking the wider strategic benefits.
Captive participation creates a more direct connection between benefits performance and financial outcomes. Employers gain greater visibility into claims trends, pharmacy utilisation and other cost drivers, strengthening the incentive to invest in prevention, claims management and population health initiatives.
Lakhanpal argues that the most significant opportunity often lies in managing the total cost of healthcare rather than simply reducing the premium paid for stop-loss protection.
“For most large self-insured employers, stop-loss premiums represent a relatively small portion of total healthcare costs,” he says. “The greater concern is volatility in claims experience within the retained layers.”
This distinction matters. A lower insurance premium might improve the immediate financial position, but greater predictability in the underlying healthcare spend can be more valuable to an organisation seeking to manage budgets over several years.
Captives can also support employers with multiple operating or portfolio companies. By aggregating risk, the captive can help reduce volatility at individual company level while retaining a broader view of the group's exposure.
The resulting underwriting income might provide additional resources for claims management and initiatives designed to address the causes of rising expenditure. In this way, the captive becomes part of a wider cost-management strategy rather than simply another financing vehicle.
The benefits are not purely financial. Greater access to data, improved governance and closer collaboration between benefits, finance and risk management teams can help organisations make better-informed decisions.
Willmanowski notes that, once savings have been achieved, “other elements like control, access to data and less visible / quantifiable efficiencies gain more importance over time”.
He adds that the longer-term opportunity is to create a benefits offering tailored to the organisation's strategy while optimising processes and freeing resources for more strategic work.
Medical stop-loss moves into focus
Medical stop-loss has emerged as a particularly prominent growth area for employee-benefit captives, especially in the US, where employers face rising claims severity and increasingly challenging renewal conditions.
Cancer remains a major driver of catastrophic claims, while high-cost cardiovascular conditions, new-born claims and specialty pharmacy expenses add further pressure. Lakhanpal notes that, in some cases, pharmacy claims for stop-loss claimants more than doubled between 2019 and 2025.
At the same time, stop-loss insurers are confronting rising claims costs and deteriorating loss ratios. The result is a harder market, with employers experiencing double-digit premium increases and less favourable renewal terms.
These conditions are strengthening the argument for retaining a portion of stop-loss risk within a captive, allowing employers to optimise the structure and cost of their risk financing rather than relying entirely on commercial cover.
However, moving medical stop-loss into a captive is not a decision to take lightly. The potential benefits must be weighed against the volatility of large claims and the capital required to support retained exposure.
“Organisations need sufficient scale, a commitment to long-term risk financing, strong data analytics capabilities, and an appropriate reinsurance strategy for a captive to be a valuable fit,” Lakhanpal cautions.
Willmanowski also stresses that US medical stop-loss has a different risk profile from more traditional employee-benefit coverages. Within international benefits arrangements, it remains an exception to the risks commonly reinsured through multinational fronting structures.
Consequently, it is generally more mature captives that begin exploring this opportunity. For employers considering the move, a thorough assessment of risk appetite, claims data, programme structure and reinsurance protection is essential.
Expanding the boundaries of benefits financing
While medical stop-loss is likely to remain a major source of growth, the longer-term opportunity extends well beyond conventional life and disability cover.
Voluntary benefits, international employee-benefit programmes, retiree medical obligations and pension-related risks are all attracting interest as employers examine whether the economics of transferring risk to commercial insurers justify the value received.
Voluntary benefits are one area where greater control and scrutiny are becoming particularly relevant. Lakhanpal points to growing fiduciary and governance pressures, including recent litigation relating to these products, as another reason employers are seeking greater visibility into their arrangements.
For multinational organisations, the evolution is likely to be gradual. Willmanowski describes a progression from bringing more fully insured expenditure into existing fronting arrangements towards assessing larger, more complex countries and lines of business, including standalone medical and substantial disability exposures.
Only once captives have developed the necessary capabilities and risk appetite are some organisations beginning to consider more specialised opportunities.
These include voluntary benefits offerings, directly written global coverages and parametric solutions for catastrophic events affecting employees. Such developments remain at an early stage in some cases, but they reflect a broader ambition to make captive structures more directly relevant to organisational and employee needs.
Pension risk transfer is another emerging possibility. Traditionally, employers seeking to reduce pension risk have relied on insurer buy-in or buy-out transactions. Captive-supported structures could offer an alternative way to pursue risk transfer objectives while improving the efficiency of the overall economic arrangement.
Lakhanpal says his team has been at the forefront of this developing strategy in the US, with growing momentum among plan sponsors carrying significant retiree liabilities.
Across these opportunities, the underlying question is consistent: whether an organisation can achieve a better balance of cost, control and risk by financing more of its employee benefits through a captive.
A longer-term view of value
The evolving case for employee-benefit captives is not simply a response to rising premiums. Nor is it a guarantee that retaining risk will always produce savings. Medical inflation, severe claims and the need for adequate capital and reinsurance remain real constraints.
Instead, the shift reflects a broader reassessment of the relationship between insurance expenditure and value received. Employers are increasingly looking beyond annual renewal outcomes towards the benefits of longer-term pricing strategies, greater data transparency and closer alignment between risk financing and benefits management.
For some organisations, the immediate attraction will be underwriting income. For others, it will be budget stability, improved governance or the opportunity to tailor benefits financing across a multinational group.
The most compelling proposition combines these advantages: retaining appropriate risk, using data to understand and manage costs and reinvesting the financial benefits in better outcomes.
In Lakhanpal's words, a captive can put employers “back in the driver's seat” of their risk financing.
As employee benefit costs continue to rise and commercial markets remain subject to cycles of hardening and softening, that greater control might prove to be the defining element of the new value calculus.
Did you get value from this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
